Immunogenicity of 9-valent HPV Vaccine

Launched by TALIA SAINZ COSTA · Jun 27, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how well the 9-valent HPV vaccine (9vHPV) works in children and adolescents who have weakened immune systems, such as those who have received organ transplants or are living with HIV. The vaccine is designed to protect against nine types of the human papillomavirus (HPV), which can cause serious health issues like cervical cancer and genital warts. While the vaccine has been shown to be effective in healthy children and teens, researchers want to understand how well it works for those who are immunocompromised, as they may need extra doses or special monitoring.

To participate in this study, children and adolescents aged 9 to 17 who are willing to take part and meet certain health criteria can apply. For example, if someone has HIV, they need to be on treatment and have a stable immune status. Participants will receive the vaccine and be monitored for their immune response. This trial is important because it aims to ensure that all children, especially those with weakened immune systems, can receive the best possible protection against HPV-related health issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children or adolescents 9 to \<18 years of age
• • Willing to sign consent/assent form
• • If HIV positive, under ART and undetectable viral load and CD4 cell count \>200/mm3 (at least 6 months)
• • If the patient has received chemotherapy or is a SOT/HSCT recipient, referred for immunizations after adequate immune reconstitution according to routine clinical practice
• Exclusion Criteria:
• • Previous history of warts and/or anal cancer.
• • Previous immunization with any HPV vaccine.
• • Age below 9.
• • Patients who for any reason should not be included in the study according to the evaluation of the research team.